Abstract The COL11A1 human gene codes for the α1 chain of procollagen 11A1 and mature collagen 11A1, an extracellular minor fibrillar collagen. Under regular conditions, this gene and its derived products are mainly expressed by chondrocytes and mesenchymal stem cells as well as osteoblasts. Normal epithelial cells and quiescent fibroblasts from diverse locations do not express them. Mesenchyme-derived tumors and related conditions, such as scleroderma and keloids, are positive for COL11A1/(pro)collagen 11A1 expression, as well as high-grade human gliomas/glioblastomas. This expression is almost absent in benign pathological processes such as breast hyperplasia, sclerosing adenosis, idiopathic pulmonary fibrosis, cirrhosis, pancreatitis, diverticulitis, and inflammatory bowel disease. By contrast, COL11A1/(pro)collagen 11A1 is highly expressed by activated stromal cells of the desmoplastic reaction of different human invasive carcinomas, and this expression is correlated with carcinoma aggressiveness and progression, and lymph node metastasis. COL11A1 upregulation has been shown to be associated to TGF-β1, Wnt, and Hh signaling pathways, which are especially active in cancerassociated stromal cells. At the front of invasive carcinomas, neoplastic epithelial cells, putatively undergoing epithelialto-mesenchymal transition, and carcinoma-derived cells with highly metastatic capabilities, can express COL11A1. Thus, in established metastases, the expression of COL11A1/ (pro)collagen 11A1 could rely on both the metastatic epithelial cells and/or the accompanying activated stromal cells. COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human carcinoma-associated stromal cells and carcinoma progression. The COL11A1 human gene codes for the α1 chain of procollagen and mature collagen of type XI, which is an extracellular minor fibrillar collagen.
Each collagen protomer is usually made of three different polypeptides, designed as α1, α2, and α3, and coded by specific gene sequences. In collagen of type XI, the α1 and α2 chains are coded by the COL11A1 and COL11A2 genes, respectively; however, the α3 chain is identical to α1 (II), coded by the COL2A1 gene, which is the main component of collagen of type II. These polypeptides are synthesized as procollagens, which include the globular Nand C-propeptides flanking the prototypical collagen triple helix. Upon secretion, the propeptides are excised by proteolytic cleavage; at the ends of the triple-helical collagen molecule, short N-and C-telopeptides remain [1] . Then, the mature collagen molecules self-assemble into fibrils, on the cell surface and/or in the extracellular matrix, through covalent cross-links between telopeptides and specific triple-helical telopeptide-binding regions [2] (Fig. 1) .
Minor fibrillar collagens of type V and XI are considered to act as nucleators, controlling the assembly of collagen fibrils, in such a way that they become mostly buried, under major fibrillar collagens I, II, and III, in the core of the mature heterotypic extracellular fibril [3] . Extracellular collagens are main components of the extracellular matrix, along with proteoglycans and glycoproteins such as fibronectin and tenascin C, among others.
In the adult, (pro)collagen 11A1 is present in the ocular vitreous, in the inner ear, in hyaline cartilage, and in the nucleus pulposus of the intervertebral disk [4] . In the latter, it is mainly produced by chondrocytes, in the case of the ocular vitreous, by keratocytes (corneal fibroblasts). It is also expressed by mesenchymal stem cells and osteoblasts [5, 6] (Fig. 2) .
Under regular conditions, normal epithelial cells and quiescent fibroblasts, from diverse locations, do not express COL11A1/(pro)collagen 11A1.
Regulation of the expression of COL11A1/(pro)collagen 11A1
So far, two transcription factors have been reported to interact with the COL11A1 promoter. Matsuo et al. [7] and Hida et al. [8] have shown that the transcription factor NF-Y regulates the proximal promoter activity of the COL11A1 gene in both cartilage and noncartilage cells. Lymphocyte enhancerbinding factor 1 (Lef1), which participates in the Wnt signaling pathway and is important in osteoblast maturation [9] , indirectly activates COL11A1.
Human mesenchymal stem cells (HMSCs), upon exposure to TGF-β1, differentiate to carcinoma-associated fibroblastlike cells and upregulate their COL11A1 expression [10] [11] [12] . In line with this, in fibroblasts, it was confirmed that TGF-β signaling activates the transcription of the COL11A1 gene [13] . Recently, TGF-β1 has been shown to upregulate NF-Y and to modulate its binding to the COL11A1 promoter, resulting in induction of COL11A1 messenger RNA (mRNA) [14] . Similarly, the activation of the Hedgehog (Hh) pathway increases the expression of COL11A1 [15] .
In cancer-associated stromal cells, several signaling activation pathways, such as the TGF-β1, Wnt, or Hh, have been identified to be active [16] [17] [18] [19] . The expression of WISP-1, a downstream mediator of the Wnt signaling pathway has been found to be correlated with the expression of COL11A1 in sporadic colorectal carcinomas [20] . Activation of Wnt signaling in stroma from pancreatic cancer is also associated to high COL11A1 expression [21] . Hh signaling promotes desmoplasia and is restricted to the stromal compartment in pancreatic cancer [22, 23] .
The COL11A1 gene is expressed in mesenchymal-type/ soft tissue human tumors such as rhabdomyosarcoma, chondrosarcoma, fibrosarcoma, osteosarcoma, or Ewing's sarcoma [24, 25] , as well as in solitary fibrous tumors [26] .
A high expression of COL11A1 has been found as well in at least some human gliomas/glioblastomas, especially of high grade; these tumors are thought to be derived from mesenchymal stem cells [27] [28] [29] [30] .
Keloids are benign dermal fibroproliferative tumors, characterized by dense nodules of collagens and fibroblasts; the TGFβ/Smad pathway is paramount in this disease. COL11A1 has been found to be overexpressed in human keloid fibroblasts related to normal skin fibroblasts [31] [32] [33] .
In scleroderma skin, another condition with extensive fibroblast activation and upregulation of the TGFβ and Wnt signaling pathways, the overexpression of COL11A1 has also been reported [34] .
Thus, according to all these observations, COL11A1 expression is mainly restricted to mesenchyme-derived cells (Fig. 2 ).
COL11A1/(pro)collagen 11A1 expression as biomarker of carcinoma-associated stromal cells and carcinoma progression Classically, fibroblasts are described as spindle-shaped stromal cells, which express mesenchymal biomarkers such as VIM/vimentin.
They can be activated under a number of conditions, and they express some additional biomarkers, such as fibroblast activation protein (FAP).
One of the conditions which leads to the activation of fibroblasts is their association to malignant tumors. They are then generically called cancer-associated fibroblasts (CAFs), a heterogeneous group which includes various stromal cell types, which along with the accompanying extracellular matrix components, build up the desmoplastic reaction. According to Togo et al. [35] , Bseveral different markers, such as α-SMA, tenascin-C (TN-C), periostin (POSTN), neuron-glial antigen2 (NG2), PDGFRα/β, fibroblast activated protein (FAP), palladin and podoplanin are reported to be useful for detecting activated stromal fibroblast populations in CAFs^; however, in strictu sensu, some of these markers are not exclusive to CAFs.
α-SMA is a general biomarker of myofibroblasts, either resting or activated. Tenascin C is highly expressed in tissue repair and chronic inflammation [36] . Periostin is expressed by airway epithelial cells [37] . In the adult intestine, NG-2/ CSPG4/MCSP expression is observed within myofibroblasts and pericytes [38] . PDGFRα/β is also expressed by fibroblasts of the idiopathic pulmonary fibrosis [39] . FAP has increased expression during tissue damage, wound healing, fibrosis, and inflammation [40] . According to Rönty [41] , palladin is widely expressed in both epithelial and mesenchymal tissues, in muscle cells, and in nonmuscle cells. As shown by Schacht et al. [42] , the lymphatic marker podoplanin is expressed by different cell types and by alveolar epithelial type I cells in lung. Some other markers, such as fibroblast surface protein and fibroblast specific protein-1 (FSP-1)/ S100A4, are not either specific of CAFs.
Under normal regular conditions, COL11A1/(pro)collagen 11A1 is not expressed in stromal cells of head and neck, breast, lung, stomach, liver, pancreas, and colon, and it is almost absent in benign pathological processes such as breast hyperplasia, sclerosing adenosis [43] , idiopathic pulmonary fibrosis, cirrhosis [44] , pancreatitis [45] , diverticulitis, and inflammatory bowel disease [46] . In invasive carcinomas, the extracellular collagens are key players of tumor behavior and are subjected to continuous remodeling in such a way that they both inhibit and promote tumor progression depending on the stage of tumor development [47] .
COL11A1/(pro)collagen 11A1 is highly expressed by activated stromal cells of the desmoplastic reaction of human invasive carcinomas of oral cavity/pharynx [48] , head and neck [49, 50] , breast [43, [51] [52] [53] [54] [55] , lung [56] [57] [58] [59] [60] , esophagus [61] , stomach [62, 63] , pancreas [44, [64] [65] [66] , colon [20, [67] [68] [69] [70] [71] , and ovary [14, 72] (Fig. 2) . In these scenarios, the expression of COL11A1/(pro)collagen 11A1 is correlated with carcinoma aggressiveness and progression, and lymph node metastasis (Table 1) .
According to Vecci et al. [62] , COL11A1 was the gene with the overall highest fold change in advanced gastric cancer in comparison with early gastric cancer. These observations were confirmed later on by Zhao et al. [63] as COL11A1 was found to be expressed by stromal cells in the vicinity of developing carcinoma in situ in stomach, increasingly with the progression of the carcinoma, allowing to distinguish between premalignant and malignant lesions.
Similarly, Freire et al. [55] , Stuetz et al. [73] , Ma et al. [74] , Lee et al. [75] , Castellana et al. [76] , and Vargas et al. [77] , reported that COL11A1/(pro)collagen 11A1 is overexpressed in invasive ductal carcinoma (IDC) of the breast relative to ductal carcinoma in situ (DCIS).
The expression of COL11A1 has also been shown to be associated with progression and poor survival of ovarian cancer patients [14, 72] . Based on in vitro observations, Sok et al. [50] reached similar conclusions regarding head and neck squamous cell cancer growth and invasion. More recently, Galván et al. [71] found that the immunodetection of procollagen 11A1 is associated with the development of distant metastases and advanced Dukes staging of human colon adenocarcinoma.
Through co-immunostainings on pancreatic ductal adenocarcinoma samples, procollagen 11A1+ cells have been shown to express some other mesenchymal markers, such as vimentin, α-SMA, or desmin in different proportions [66] , which confers to them an Bactivated myofibroblast-like^phe-notype. In all the different types of human invasive carcinomas so far studied, these cells are mainly peritumoral, located around the tumor foci. It is intriguing that only a fraction of the peritumoral spindle-shaped α-SMA+ myofibroblast-like cells are procollagen 11A1+. Since it has been shown that some carcinoma-associated stromal cells are in part derived from mesenchymal progenitors and some of these progenitors express COL11A1/(pro)collagen 11A1, it has been suggested that peritumoral procollagen 11A1+ cells could be a more specialized subpopulation of activated myofibroblasts [71] . Although COL11A1 has been reported to be expressed to some extent by vascular smooth muscle cells [78] and tumor endothelial cells [79] , immunostaining of blood vessel walls has never been observed with the highly specific anti-human procollagen 11A1 DTMX1/1E8.33 mAb [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] 71] .
COL11A1/(pro)collagen 11A1 in EMT and metastases
At present, there are three recognized subtypes of Bepithelialto-mesenchymal transition^(EMT) [80, 81] . Type 3 EMT occurs at the invasive front of carcinomas in such a way that carcinoma cells lose adhesiveness and acquire motility and migration capabilities. Traits associated with a type 3 EMT are the acquisition of a spindle shape, the upregulation of vimentin (VIM), and the Bcadherin switching,^consisting in the progressive loss of E-cadherin (CDH1) and the increase in N-cadherin and OB-cadherin or cadherin-11 (CDH11) expression. Together with this, EMT is also associated with the upregulation of some transcription regulators such as SNAI1 (Snail), SNAI2 (Slug), TWIST1 (Twist), and ZEB2 (SIP1) [81, 82] .
It remains a matter of speculation and controversy what the origin and/or nature of the cells is which, at the front of human invasive carcinomas, express COL11A1/(pro)collagen 11A1 [72, 77, 83, 84] ; this aspect warrants further detailed study (see more below).
The development of distant metastases is the major cause of death from some carcinomas. These metastases originate from small tumor emboli, which separate from the primary tumor mass, and, through bloodstream or lymphatics, reach and nestle into another body location. These emboli are not usually accompanied by stromal components but, in the establishment of pancreatic cancer metastasis, the comigration of pancreatic stellate cells and tumor cells has been demonstrated [85] .
Transcription profiling observations from circulating breast and prostate cancer cells indicate that these cells do not express COL11A1; in contrast, expression of cadherin-11-a surface adhesion molecule, which establishes interactions with stromal cells for anchorage and nesting of distant metastases-has been shown to be associated with a circulating and metastasizing phenotype of these cancer cells [86] [87] [88] [89] . Tumor progression, lymph node metastasis, poor prognosis [14, 72] The overexpression of COL11A1 has been correlated with a multicancer metastasis-associated gene expression signature [90] and with lymph node metastasis of nonsmall lung cancer [57] . Reports on the differential expression of COL11A1 between primary breast tumors and lymph node metastases have pointed toward a higher expression in the primary tumors [91] [92] [93] .
These studies did not pay special attention to the kind of cells which express COL11A1 in metastases; moreover, so far, there have not been detailed reports on the immunodetection of (pro)collagen 11A1 in metastases of human invasive carcinomas.
While COL11A1/(pro)collagen 11A1+ cells seem to be predominantly activated stromal cells in the primary tumor, some observations indicate that carcinoma-derived cells, with high metastatic capabilities, can express COL11A1 [94, 95] . The SNU182 poorly differentiated hepatocellular carcinoma cell line expresses high levels of COL11A1, along with cadherin-1 and mesenchymal markers such as vimentin, SNAI1 (Snail), SNAI2 (Slug), TWIST1 (Twist), and TWIST2 [94] . Lungmetastatic LM2 cells, originally derived from the clear cell renal (RCC) carcinoma SN12C cell line, have been shown to have a highly upregulated COL11A1 gene [95] .
According to the Gene Expression Atlas, ArrayExpress E-MTAB-37 [96] , one of the human cancer cell lines with the highest COL11A1-specific mRNA expression is the large cell lung carcinoma NCI-H661. This cell line was derived from the lymph node of a patient with large cell cancer of the lung. We have assessed by immunocytochemistry that this cell line expresses high levels of procollagen 11A1 as well (Fig. 3) .
Therefore, in established metastases, the expression of COL11A1/(pro)collagen 11A1 could originate from both the metastatic epithelial cells and/or the accompanying activated stromal cells.
Conclusion
In summary, under the influence of various growth factors and signaling pathways which are known to be active in carcinomas and promote COL11A1 expression, we may conclude that COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human carcinoma-associated stromal cells and carcinoma progression. In agreement with this, a very recent review by Raglow and Thomas [97] highlights the role of COL11A1/(pro)collagen 11A1 in cancer.
